Skip to main content
Retour
Watch Compare

Metagenomi Therapeutics, Inc.

Qualité des données : 100%
MGX
NASDAQ Manufacturing Chemicals
1,44 €
▼ 0,01 € (-0,35%)
6 months return
—
Momentum
Neutral
ROE
-46,95%

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-51,79%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-46,95%
Au-dessus de la moyenne du secteur (-54,47%)
ROIC-33,17%
Net Margin-348,54%
Op. Margin-380,85%

Sécurité

Debt / Equity
N/A
Current Ratio6,42
Interest CoverageN/A

Valorisation

PE (TTM|NTM)
-0,59 | -0,86
Au-dessus de la moyenne du secteur (-1,50)
P/B Ratio0,29
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -89,47 M
Capital efficient — spends only 2,28% of revenue on capex

Price History

Tendances Financières

Objectif de Cours des Analystes

3 analystes
Buy
+550.4%
upside to target
Actuel
1,44 €
Consensus Target
9,33 €
7,00 €
Bas
12,00 €
Haut
Prévisions
P/E Prévisionnel
-0,86
BPA Prévisionnel
-1,67 €
CA Est.
21,50 M

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -0,55 € · Rev Est: 5,93 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -0,68 € -0,54 € -0,55 € -0,60 € — —
Estimate -0,51 € -0,61 € -0,53 € -0,59 € -0,55 € -0,58 €
Surprise -33,33% +11,96% -3,13% -2,56% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) -51,79% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -46,95% · Net Margin: -348,54%
Revenue (TTM) 25,21 M Net Income (TTM) -87,87 M
ROE -46,95% ROA -33,78%
Gross Margin N/A Operating Margin -380,85%
Net Margin -348,54% Free Cash Flow (TTM) -89,47 M
ROIC -33,17% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 6,42
Debt / Equity N/A Current Ratio 6,42
Interest Coverage N/A Asset Turnover 0,10
Working Capital 160,24 M Tangible Book Value 178,45 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,59 · EV/EBITDA: N/A
P/E Ratio -0,59 Forward P/E -0,86
P/B Ratio 0,29 P/S Ratio 2,05
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 2,41 Fwd Earnings Yield N/A
FCF Yield -172,95%
Market Cap 51,73 M Enterprise Value 18,96 M

Per Share

EPS: -2,36 · FCF/Share: -2,38
EPS (Diluted TTM) -2,36 Revenue / Share 0,67
FCF / Share -2,38 OCF / Share -2,36
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 101,82% · CapEx/Rev: 2,28%
CapEx / Revenue 2,28% FCF Conversion 101,82%
SBC-Adj. FCF -103,68 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 25,21 M 52,30 M
Net Income -87,87 M -78,06 M
EPS (Diluted) -2,36 -2,36
Gross Profit — —
Operating Income -96,01 M -88,90 M
EBITDA — —
R&D Expenses 94,43 M 109,18 M
SG&A Expenses — —
D&A — —
Interest Expense — —
Income Tax -58 000,0 -5,51 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 221,10 M 324,60 M
Total Liabilities 62,51 M 89,74 M
Shareholders' Equity 158,60 M 234,86 M
Total Debt — —
Cash & Equivalents 41,72 M 27,39 M
Current Assets 165,54 M 257,96 M
Current Liabilities 22,93 M 37,31 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -0,6 -1,5
P/B 0,3 1,6
ROE % -47,0 -54,5
Net Margin % -348,5 -41,5
Rev Growth 5Y % — 1,9
D/E — 0,3

ETFs Holding This Stock
BRUSX BRUSX
0,59% weight
BRSIX BRSIX
0,13% weight
AVDS logo AVDS Avantis International Small Cap Equity ETF
0,00% weight
AVDVX AVDVX
0,00% weight
AVANX AVANX
0,00% weight
AVDNX AVDNX
0,00% weight